Sanofi-Aventis says Taxotere shows good results in non-small cell lung cancer |
|
|
|
Published
:
Tue, 04 Sep 2007 07:13
|
PARIS (Thomson Financial) - Pharmaceutical company Sanofi-Aventis said seven trials of its Taxotere drug in treating non-small cell lung cancer showed a 'significant' improvement in overall survival rates versus existing treatments.Taxotere, an anti-cancer agent used in other treatments, is the company's fourth best-selling drug.tfn.paris@thomson.commjs/jlwCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2378.01 |
+15.80 (
0.67 %)
|
| SYMBOL (
2010-03-16 ) |
| LAST |
CHANGE
|
|
RIO TINTO
(
12:35pm )
|
|
3702.00 |
+45.00 (
1.22 %)
|
|
NEXT
(
12:35pm )
|
|
2034.00 |
+25.00 (
1.24 %)
|
|
KAZAKHMYS
(
12:35pm )
|
|
1496.00 |
+23.00 (
1.56 %)
|
| SYMBOL (
2010-03-16 )
|
| LAST |
CHANGE
|
|
INTEL CP
(
4:00pm ) |
|
22.01 |
+0.84 (
3.96 %)
|
|
IBM
(
4:00pm ) |
|
128.67 |
+0.84 (
0.66 %)
|
| SYMBOL (
2010-03-16 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Sanofi-Aventis and Regeneron begin phase 3 trials of cancer drug 